Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.65% -0.03% 257.57M 64211.70
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.47% 460.0% 124.74M Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the Lunt Capital Large Cap Factor Rotation Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks that comprise the index. The index utilizes the index provider's risk-adjusted relative strength methodology to allocate exposure to securities exhibiting either high or low levels of the characteristics associated with one of four primary investing factors: momentum, value, quality and volatility. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Value
Fixed Income Style --
Broad Asset Class US Equity
Broad Category Equity
Category Name Large Blend
Category Index Russell 1000 TR USD
Prospectus Objective Growth
Fund Owner Firm Name First Trust
Prospectus Benchmark Index
Lunt Capital LC Factor Rotation USD 100.0%
Broad Asset Class Benchmark Index
^SPXTR 100.0%
Manager Tenure
Chris Peterson 2.78 yrs
Daniel Lindquist 2.78 yrs
David McGarel 2.78 yrs
Jon Erickson 2.78 yrs
Roger Testin 2.78 yrs
Stan Ueland 2.78 yrs
Erik Russo 0.33 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 12
124.74M
-25.72B Category Low
14.89B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of April 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of May 12, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
--
--
--
30.90%
30.15%
14.40%
13.69%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
8.74%
--
--
--
--
--
29.34%
15.14%
16.15%
15.12%
-2.30%
13.31%
24.41%
-6.28%
29.54%
13.97%
13.31%
14.06%
-2.66%
14.50%
18.51%
-7.82%
28.91%
12.71%
15.00%
17.28%
4.01%
10.09%
17.32%
-0.18%
27.87%
-1.37%
7.74%
As of May 12, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-13-21) 0.47%
30-Day SEC Yield (3-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 20.54
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 12, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 12, 2021

Asset Allocation

As of May 11, 2021.
Type % Net % Long % Short
Cash 0.03% Upgrade Upgrade
Stock 99.97% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Vertex Pharmaceuticals Inc 2.35% 214.27 0.75%
Regeneron Pharmaceuticals Inc 2.28% 517.00 1.94%
Biomarin Pharmaceutical Inc 2.12% 75.51 -0.12%
Seagen Inc Ordinary Shares 2.08% 144.78 0.01%
Clorox Co 1.95% 182.67 0.38%
Splunk Inc 1.85% 111.92 -3.26%
Merck & Co Inc 1.59% 78.57 0.73%
O'Reilly Automotive Inc 1.54% 554.80 1.19%
Gilead Sciences Inc 1.53% 68.80 2.00%
Viatris Inc 1.50% 15.96 1.53%

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the Lunt Capital Large Cap Factor Rotation Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks that comprise the index. The index utilizes the index provider's risk-adjusted relative strength methodology to allocate exposure to securities exhibiting either high or low levels of the characteristics associated with one of four primary investing factors: momentum, value, quality and volatility. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Value
Fixed Income Style --
Broad Asset Class US Equity
Broad Category Equity
Category Name Large Blend
Category Index Russell 1000 TR USD
Prospectus Objective Growth
Fund Owner Firm Name First Trust
Prospectus Benchmark Index
Lunt Capital LC Factor Rotation USD 100.0%
Broad Asset Class Benchmark Index
^SPXTR 100.0%
Manager Tenure
Chris Peterson 2.78 yrs
Daniel Lindquist 2.78 yrs
David McGarel 2.78 yrs
Jon Erickson 2.78 yrs
Roger Testin 2.78 yrs
Stan Ueland 2.78 yrs
Erik Russo 0.33 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-13-21) 0.47%
30-Day SEC Yield (3-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 20.54
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 12, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 12, 2021

Fund Details

Key Dates
Inception Date 7/23/2018
Last Annual Report Date 12/31/2020
Last Prospectus Date 5/3/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No